恒生创新药ETF（159316）连续3日“吸金”，最新规模超11亿元，创历史新高

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index fell by 1.3%, while the CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index decreased by 0.9% [1] - The CSI Innovative Drug Industry Index declined by 0.4%, whereas the CSI Biotech Theme Index increased by 0.1% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 21 million units today, marking three consecutive days of net inflow, with the latest scale reaching 1.15 billion yuan, a historical high [1] Group 2 - The recent revision of the Hang Seng Hong Kong Stock Connect Innovative Drug Index's compilation plan has taken effect, explicitly excluding CXO companies and focusing on innovative drug companies, achieving a "purity" of 100% for the first time among ETF tracking indices [1] - Backtesting data indicates that since the adjustment, the index has shown higher annualized returns and Sharpe ratios since its launch on July 10, 2023 [1]